Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

Adams, R; Brown, E; Brown, L; Butler, R; Falk, S; Fisher, D; Kaplan, R; ... FOCUS4 Trial Investigators, ; + view all Adams, R; Brown, E; Brown, L; Butler, R; Falk, S; Fisher, D; Kaplan, R; Quirke, P; Richman, S; Samuel, L; Seligmann, J; Seymour, M; Shiu, KK; Wasan, H; Wilson, R; Maughan, T; FOCUS4 Trial Investigators, ; - view fewer (2018) Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial. The Lancet Gastroenterology & Hepatology , 3 (3) pp. 162-171. 10.1016/S2468-1253(17)30394-1 . Green open access

http://ift.tt/2FJmmAw